1️⃣ Psychedelics just got a federal fast lane

The White House signed an April 18 order directing priority vouchers for eligible breakthrough-designated psychedelic drugs, a Right to Try access path and at least $50M for state-linked research.

💡 Why it matters

It does not approve a drug. It shortens the path to one and lowers the policy discount investors usually apply to the category.

☕ Coffee talk

How many models still price this space like fringe science when Washington just put a clock on it?


2️⃣ Roche is buying MRD scale, not just another test

Roche agreed on April 16 to buy SAGA Diagnostics for up to $595M, adding Pathlight, a tumor-informed MRD platform already covered by Medicare in early-stage breast cancer.

💡 Why it matters

MRD is moving from specialist assay to monitoring stack. Roche is paying early to own a platform before recurrence testing spreads across more tumor types.

☕ Coffee talk

MRD is still supposed to be early, so why are the big platforms already shopping like the category is decided?


3️⃣ AstraZeneca now has a third pivotal COPD win

AstraZeneca said on April 20 that tozorakimab met the primary endpoint in the Phase III MIRANDA trial, reducing moderate-to-severe COPD exacerbations on top of inhaled standard care.

💡 Why it matters

A third pivotal win matters more than the first two. It makes IL-33 look closer to a filing path than another interesting mechanism.

☕ Coffee talk

Does this finally make COPD a biologics market, or do payers still treat it like an expensive inhaler add-on?